$ITeos Therapeutics (ITOS.US)$In the past 4 years, 2021 alon...

However, revenue declined all the way in the first three quarters of 2022, but overall it reached 214 million, operating profit reached 111 million, and net profit was 76 million. The company has no interest charges.

The balance sheet shows that current assets reached 770 million, liabilities 144 million, and net current assets reached 630 million, which is comparable to the current total market value.

Currently, the price-earnings ratio is TTM2.6, and the price-earnings ratio is 3.2. The only question is whether revenue is sustainable. After all, revenue has already declined from 153 million to 0.2 million in the past two quarters. Taken together, it is possible to carefully monitor positions (⭐️).